

# Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/SAB77FB754E8EN.html>

Date: November 2022

Pages: 63

Price: US\$ 2,000.00 (Single User License)

ID: SAB77FB754E8EN

## Abstracts

Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Drugs In Development, 2022, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 11 and 2 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Short Bowel Syndrome - Overview

Short Bowel Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Short Bowel Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Short Bowel Syndrome - Companies Involved in Therapeutics Development

9 Meters Biopharma Inc

Amogen Pharma Pvt Ltd

Applied Molecular Transport Inc

enGene Inc

Entera Bio Ltd

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Micelle BioPharma Inc

Napo Pharmaceuticals Inc

OPKO Health Inc

PhaseBio Pharmaceuticals Inc

QuiaPEG Pharmaceuticals AB

Surrozen Inc

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

VectivBio Holding AG

Worphmed Srl

Zealand Pharma AS

Short Bowel Syndrome - Drug Profiles

apraglutide - Drug Profile

Product Description

Mechanism Of Action

Bispecific Monoclonal Antibody for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action  
crofelemer DR - Drug Profile  
Product Description  
Mechanism Of Action  
Gene Therapy for Short Bowel Syndrome - Drug Profile  
Product Description  
Mechanism Of Action  
glepaglutide - Drug Profile  
Product Description  
Mechanism Of Action  
GLP-2 - Drug Profile  
Product Description  
Mechanism Of Action  
GLP-2 - Drug Profile  
Product Description  
Mechanism Of Action  
GLP2-ELP - Drug Profile  
Product Description  
Mechanism Of Action  
GXG-8 - Drug Profile  
Product Description  
Mechanism Of Action  
HL-06 - Drug Profile  
Product Description  
Mechanism Of Action  
HM-15912 - Drug Profile  
Product Description  
Mechanism Of Action  
melatonin - Drug Profile  
Product Description  
Mechanism Of Action  
MOD-1501 - Drug Profile  
Product Description  
Mechanism Of Action  
NB-1002 - Drug Profile  
Product Description  
Mechanism Of Action  
QPG-1030 - Drug Profile  
Product Description

Mechanism Of Action

SC-403 - Drug Profile

Product Description

Mechanism Of Action

teduglutide - Drug Profile

Product Description

Mechanism Of Action

teduglutide - Drug Profile

Product Description

Mechanism Of Action

vurolenatide - Drug Profile

Product Description

Mechanism Of Action

Short Bowel Syndrome - Dormant Projects

Short Bowel Syndrome - Discontinued Products

Short Bowel Syndrome - Product Development Milestones

Featured News & Press Releases

Nov 03, 2022: VectivBio announces completion of enrollment for colon-in-continuity (CIC) cohort of STARS pivotal phase 3 study investigating apraglutide in short bowel syndrome with intestinal failure (SBS-IF)

Oct 13, 2022: VectivBio reports positive interim clinical data from STARS nutrition, a phase 2 study investigating apraglutide in short bowel syndrome with intestinal failure patients (SBS-IF) with Colon-In-Continuity (CIC)

Oct 03, 2022: Zealand Pharma reports data from Phase III short bowel syndrome trial

Sep 26, 2022: 9 Meters Biopharma announces positive final results from phase 2 vibrant study and successful end-of-phase 2 meeting with FDA for vurolenatide in short bowel syndrome

Jul 13, 2022: 9 Meters Biopharma to participate in the William Blair Biotech Focus Conference 2022

Jun 30, 2022: 9 Meters Biopharma announces debt facility to support phase 3 study of vurolenatide for short bowel syndrome

Jun 30, 2022: 9 Meters Biopharma announces positive preliminary results from phase 2 study of vurolenatide in short bowel syndrome

Jun 01, 2022: NICE recommends Revestive (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)

May 05, 2022: 9 Meters Biopharma to present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium

Mar 29, 2022: VectivBio presents new clinical data supporting apraglutide for treatment of short bowel syndrome with intestinal failure (SBS-IF) patients who have renal

dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference

Mar 21, 2022: 9 Meters Biopharma to present the clinical milestones for vurolenatide at the Maxim Group 2022 Virtual Growth Conference

Feb 28, 2022: 9 Meters Biopharma provides clinical update on late-stage pipeline product vurolenatide for short bowel syndrome

Jan 20, 2022: Zealand Pharma completes enrollment in EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome

Dec 16, 2021: Zealand Pharma announces enrollment of last patient needed for interim analysis of EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome

Dec 13, 2021: European Medicines Agency grants Orphan Drug Designation for crofelemer to Napo EU, Jaguar Health's Italian Subsidiary, for Short Bowel Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Short Bowel Syndrome, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Short Bowel Syndrome - Pipeline by 9 Meters Biopharma Inc, 2022  
Short Bowel Syndrome - Pipeline by Amogen Pharma Pvt Ltd, 2022  
Short Bowel Syndrome - Pipeline by Applied Molecular Transport Inc, 2022  
Short Bowel Syndrome - Pipeline by enGene Inc, 2022  
Short Bowel Syndrome - Pipeline by Entera Bio Ltd, 2022  
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022  
Short Bowel Syndrome - Pipeline by Huons Global Co Ltd, 2022  
Short Bowel Syndrome - Pipeline by Micelle BioPharma Inc, 2022  
Short Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, 2022  
Short Bowel Syndrome - Pipeline by OPKO Health Inc, 2022  
Short Bowel Syndrome - Pipeline by PhaseBio Pharmaceuticals Inc, 2022  
Short Bowel Syndrome - Pipeline by QuiaPEG Pharmaceuticals AB, 2022  
Short Bowel Syndrome - Pipeline by Surrozen Inc, 2022  
Short Bowel Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, 2022  
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022  
Short Bowel Syndrome - Pipeline by VectivBio Holding AG, 2022  
Short Bowel Syndrome - Pipeline by Worphmed Srl, 2022  
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, 2022  
Short Bowel Syndrome - Dormant Projects, 2022  
Short Bowel Syndrome - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Short Bowel Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Short Bowel Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/SAB77FB754E8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SAB77FB754E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

